NCT04305587 - Multiple Escalating Oral Doses Study of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 16, 2020

Primary Completion Date

July 14, 2021

Study Completion Date

July 14, 2021

Conditions

Diabetes Mellitus Type 2

Interventions

DRUG

PF-07081532

Investigational Drug once daily for up to 42 days; multiple ascending dose design.

OTHER

Placebo

Placebo once daily for up to 42 days.

DRUG

Clopidogrel

Part B may include a drug-drug interaction study using open-label clopidogrel. Clopidrogrel may be given as two single doses of 75 mg administered on day -2 and day 41.

Trial Locations (2)

33143

Qps-Mra, Llc, South Miami

92801

Anaheim Clinical Trials, LLC, Anaheim